Editorial
doi: 10.1016/j.ygyno.2003.10.031.
Uterine papillary serous carcinomas: the exigency for clinical trials
- PMID: 14675662
- DOI: 10.1016/j.ygyno.2003.10.031
Item in Clipboard
Editorial
Uterine papillary serous carcinomas: the exigency for clinical trials
Gynecol Oncol.
2003 Dec.
No abstract available
Comment on
-
Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases.Gynecol Oncol. 2003 Dec;91(3):463-9. doi: 10.1016/j.ygyno.2003.08.018. Gynecol Oncol. 2003. PMID: 14675663 Review.
-
Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy.Gynecol Oncol. 2003 Dec;91(3):470-5. doi: 10.1016/j.ygyno.2003.08.027. Gynecol Oncol. 2003. PMID: 14675664
Similar articles
-
Uterine papillary serous carcinoma: what have we learned over the past quarter century?Gynecol Oncol. 2005 Sep;98(3):341-3. doi: 10.1016/j.ygyno.2005.07.006. Gynecol Oncol. 2005. PMID: 16111527 No abstract available.
-
[Uterine papillary serous carcinoma].Ginekol Pol. 1994 Oct;65(10):587-92. Ginekol Pol. 1994. PMID: 7729721 Polish.
-
Uterine papillary serous carcinoma in a 32-year-old with Turner's syndrome.Gynecol Oncol. 1994 Mar;52(3):395-401. doi: 10.1006/gyno.1994.1068. Gynecol Oncol. 1994. PMID: 8157198
-
[Precursor lesions of type II endometrial cancer: diagnostic criteria and pathogenesis].Zhonghua Bing Li Xue Za Zhi. 2007 Aug;36(8):505-7. Zhonghua Bing Li Xue Za Zhi. 2007. PMID: 17980094 Review. Chinese. No abstract available.
-
[Uterine papillary serous carcinoma--a different kind of tumor].Harefuah. 1999 May 16;136(10):810-2. Harefuah. 1999. PMID: 10955120 Review. Hebrew. No abstract available.
Cited by
-
A retrospective study evaluating the effect of trastuzumab addition to carboplatin/paclitaxel on overall survival in patients with advanced-stage HER2/neu-overexpressing uterine serous carcinoma or carcinosarcoma.BMC Med. 2025 Feb 21;23(1):99. doi: 10.1186/s12916-025-03916-3. BMC Med. 2025. PMID: 39984939 Free PMC article.
-
Promising novel therapies for the treatment of endometrial cancer.Gynecol Oncol. 2010 Feb;116(2):187-94. doi: 10.1016/j.ygyno.2009.10.041. Epub 2009 Nov 10. Gynecol Oncol. 2010. PMID: 19903572 Free PMC article. Review.
-
Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel.Oncotarget. 2018 Aug 10;9(62):31985-31998. doi: 10.18632/oncotarget.25868. eCollection 2018 Aug 10. Oncotarget. 2018. PMID: 30174791 Free PMC article.
-
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.Clin Cancer Res. 2020 Aug 1;26(15):3928-3935. doi: 10.1158/1078-0432.CCR-20-0953. Epub 2020 Jun 29. Clin Cancer Res. 2020. PMID: 32601075 Free PMC article. Clinical Trial.
-
Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.Cancer. 2013 Jul 15;119(14):2582-92. doi: 10.1002/cncr.28017. Epub 2013 Apr 12. Cancer. 2013. PMID: 23585021 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
